Xilio Therapeutics (XLO) Non-Current Debt (2020 - 2023)

Xilio Therapeutics (XLO) has 4 years of Non-Current Debt data on file, last reported at $1.5 million in Q1 2023.

• For the quarter ending Q1 2023, Non-Current Debt fell 80.68% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2023 stood at $1.5 million (down 80.68% YoY), and the FY2022 full-year result was $3.2 million, down 67.13% from the prior year.
• Non-Current Debt fell to $1.5 million in Q1 2023, from $3.2 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $9.6 million in Q4 2021 to a low of $1.5 million in Q1 2023.
• A 4-year average of $6.3 million and a median of $6.9 million in 2020 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt climbed 29.9% in 2021 and plunged 80.68% in 2023, its largest moves.
• Tracing XLO's Non-Current Debt over 4 years: stood at $7.4 million in 2020, then advanced by 29.9% to $9.6 million in 2021, then sank by 67.13% to $3.2 million in 2022, then sank by 51.09% to $1.5 million in 2023.
• Business Quant data shows XLO's Non-Current Debt at $1.5 million in Q1 2023, $3.2 million in Q4 2022, and $4.8 million in Q3 2022.